Search Results
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Company's myelofibrosis program. Following continued constructive engagement with the U.S. Food and Drug Administration (FDA), the Company remains on track to submit its planned supplemental New Drug Application (sNDA) in August under the Accelerated Approval pathway for selinexor in combination with
More news about: Karyopharm Therapeutics Inc.
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
anticipates growth starting in 2027.Recently, the Company held a pre-supplemental Biologics License Application (sBLA) meeting with the U.S. Food and Drug Administration (FDA), during which the LOTIS-5 data was discussed. Following FDA meeting feedback regarding the benefit-risk observed in the LOTIS-5
More news about: ADC Therapeutics SA
Aug 13, 2026, 07:00 ET Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
and dysregulation of NOD/RIPK2 is implicated in several inflammatory and autoimmune diseases. AC-101 was developed from Accro Bioscience's proprietary drug discovery platform targeting regulatory cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China,
More news about: Accro Bioscience Inc.
Aug 13, 2026, 04:12 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Aug 12, 2026, 21:00 ET ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been approved by the National Medical Products Administration (NMPA) of China, making AK0406 the first influenza AFC drug to enter clinical
More news about: Shanghai Ark Biopharmaceutical Co., Ltd.
Aug 12, 2026, 21:00 ET ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been approved by the National Medical Products Administration (NMPA) of China, making AK0406 the first influenza AFC drug to enter clinical
More news about: Shanghai Ark Biopharmaceutical Co., Ltd.
Aug 12, 2026, 20:17 ET XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026
from the Massachusetts Institute of Technology (MIT). The company is a technology platform focused on quantum physics-based and AI-driven innovation in drug and materials discovery. By integrating quantum physics, artificial intelligence, cloud computing, and large-scale automation, XtalPi provides research
More news about: XtalPi Holdings Limited
Aug 12, 2026, 16:05 ET Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
comments raised in the EOP2 meeting written response.Completed the validation and certification of essential lot release assays for drug substance and drug product.Completed four engineering runs of AP-SA02 at the Company's in-house current Good Manufacturing Practices ("cGMP") manufacturing
More news about: Armata Pharmaceuticals, Inc.
Aug 12, 2026, 16:05 ET INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026Commercial preparations
More news about: INOVIO Pharmaceuticals, Inc.
Aug 12, 2026, 16:05 ET Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).This release is intended for investors only. For additional information about Talphera, please visit
More news about: Talphera, Inc.
Aug 12, 2026, 16:01 ET PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
associated with chronic Enzyme Replacement Therapy (ERT). ST-920 has received Regenerative Medicine Advanced Therapy (RMAT) designation as well as Orphan Drug and Fast Track designations from FDA.The Phase 1/2 STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR)
More news about: PTC Therapeutics, Inc.
Aug 12, 2026, 16:00 ET AWH Reports Second Quarter 2026 Financial Results
split of the Company's Class A common stock in support of a planned uplisting to a major U.S. exchange.Submitted applications with the U.S. Drug Enforcement Administration ("DEA") to register certain state-licensed medical cannabis operations under the expedited registration pathway established
More news about: Ascend Wellness Holdings, Inc.
Aug 12, 2026, 15:12 ET BioCare Earns Fourth Consecutive Inc. 5000 Recognition as New Model for Independent Specialty Drug Distribution Gains Momentum
continued growth, driven by strategic investments and innovative partnerships, including the BioCareSD and AllyGPO alliance, which has reimagined specialty drug distribution and group purchasing for independent community oncology and retina practices. Together, the organizations deliver
More news about: BioCare
Aug 12, 2026, 13:34 ET Shatterproof Walk to End Addiction Returns to Dallas as Community Rallies Around Recovery and Hope
as part of Shatterproof's national effort to transform how addiction is prevented, treated, and understood in America.Although Dallas County drug overdose deaths decreased by 15% in 2024, 529 people still lost their lives to overdose. Non-fatal opioid-related EMS responses increased by 4%, with
More news about: Shatterproof
Aug 12, 2026, 13:33 ET Shatterproof Walk to End Addiction Returns to D.C. as Community Rallies Around Recovery and Hope
transform how addiction is prevented, treated, and understood in America.Although drug overdose deaths in Washington, D.C. decreased by 31% in 2024, 446 people still lost their lives to overdose. Non-fatal drug overdose hospitalizations also declined, but 538 Washington, D.C. residents were hospitalized
More news about: Shatterproof
Aug 12, 2026, 13:33 ET Shatterproof Walk to End Addiction Returns to Los Angeles as Community Rallies Around Recovery and Hope
America.Although Los Angeles County drug overdose deaths decreased by 21% in 2024, 1,791 people still lost their lives to overdose. Non-fatal drug overdose hospitalizations also declined by 9%, but 3,819 Los Angeles County residents were hospitalized in 2024. Most drug overdose deaths and non-fatal hospitalizations
More news about: Shatterproof
Aug 12, 2026, 13:15 ET CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline
allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).The HOPE-3 Trial Breakthrough and Subsequent Capital RaiseOn
More news about: Hagens Berman Sobol Shapiro LLP
Aug 12, 2026, 13:12 ET American Ventures CEO Shravan Parsi Joins Bisnow Panel on Austin's Mixed-Use Future
americanventures.com.About Shravan ParsiShravan Parsi is the CEO and Founder of American Ventures. A former pharmaceutical scientist who developed patented drug products before turning to real estate, he bought his first Texas investment property in 2003 and has since invested in roughly 4,400 multifamily units
More news about: American Ventures
Aug 12, 2026, 10:31 ET CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
development programs across the FDA's biologics and drug review centers.In April 2026, Autolus Therapeutics unveils new ROKA Real-World and pediatric data supporting obe-cel in ALL.In January 2026, the FDA awarded Orphan Drug Designation (ODD) to CTD402, an innovative allogeneic
More news about: DelveInsight Business Research, LLP
Aug 12, 2026, 10:07 ET WSE UPCOMING DEADLINE: Levi & Korsinsky Alerts Wise Group plc Stockholders of Securities Class Action - Contact the Firm
monitoring systems described as reviewing hundreds of data points in real time were inadequate to detect laundering, fraud, corruption and drug trafficking links.The lawsuit contends disclosure of a pending national trust bank application was positioned so as to minimize the risk that
More news about: Levi & Korsinsky, LLP
Aug 12, 2026, 10:01 ET Cancer Tumor Profiling Market worth $19.87 billion by 2031 - Exclusive Report by MarketsandMarkets™
and stronger pharmaceutical–diagnostic collaborations are also supporting the adoption of tumor profiling across routine care, clinical trials, and drug development.Assays, kits, reagents, and consumables accounted for the largest share of the global cancer tumor profiling market, by offering,
More news about: MarketsandMarkets
Aug 12, 2026, 10:00 ET PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
applications.Eratrectinib marks Nanjing's first innovative drug approval this year. Through innovative cyclic structural optimization, it delivers more potent and highly selective inhibition of TRK kinases, overcoming structural limitations and drug‑resistance drawbacks of first‑generation agents at the
More news about: Jiangsu Vcare Pharmatech Co., Ltd.
Aug 12, 2026, 10:00 ET Integrity Partners with Fast-Growing Meraz Health Insurance Agency to Bring AI-Enhanced Client Support to More Americans
AgencyMeraz Health Insurance Agency is a Temecula, California-based insurance brokerage specializing in Medicare Advantage, prescription drug and Medicare supplement plans. The firm has a successful, decade-long track record and deep commitment to the Latino community. It has also developed
More news about: Integrity
Aug 12, 2026, 09:01 ET Propel Bio Partners Highlights Progress of EIT Pharma Under Leadership of CEO Dr. Leen Kawas
hepatitis D (CHD), and Lambda, its Phase 2 investigational treatment for severe acute viral respiratory infections. FDA recently accepted Lonafarnib's New Drug Application which follows Lonafarnib completing its D-LIVR study, the largest clinical trial conducted to date in chronic hepatitis D, which enrolled
More news about: Propel Bio Partners
Aug 12, 2026, 09:00 ET New study from CVS Caremark and Employee Benefit News shows how employers rely on their pharmacy benefit manager to create sustainable pharmacy solutions
working with drug manufacturers to negotiate affordable drug prices for
More news about: CVS Health